Jeff Sperinde

1.4k total citations
35 papers, 611 citations indexed

About

Jeff Sperinde is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Jeff Sperinde has authored 35 papers receiving a total of 611 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 27 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Cancer Research. Recurrent topics in Jeff Sperinde's work include HER2/EGFR in Cancer Research (32 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Breast Cancer Treatment Studies (8 papers). Jeff Sperinde is often cited by papers focused on HER2/EGFR in Cancer Research (32 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Breast Cancer Treatment Studies (8 papers). Jeff Sperinde collaborates with scholars based in United States, Austria and Poland. Jeff Sperinde's co-authors include John Winslow, Michael Bates, Weidong Huang, Allan Lipton, Jodi Weidler, Wolfgang J. Köstler, Kim Leitzel, Agnès Paquet, Elicia Penuel and Rajiv Dua and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Jeff Sperinde

33 papers receiving 597 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeff Sperinde United States 15 495 337 193 124 88 35 611
Marcia R. Campbell United States 9 343 0.7× 210 0.6× 255 1.3× 103 0.8× 72 0.8× 10 512
Xander Munroe United States 2 426 0.9× 315 0.9× 246 1.3× 64 0.5× 38 0.4× 2 530
Josep Lluís Parra-Palau Spain 9 389 0.8× 264 0.8× 239 1.2× 53 0.4× 77 0.9× 14 570
Ioannis Roxanis United Kingdom 10 306 0.6× 172 0.5× 187 1.0× 88 0.7× 61 0.7× 18 553
Yen-Chao Wang United States 3 322 0.7× 140 0.4× 167 0.9× 69 0.6× 85 1.0× 3 422
M. Pegram United States 6 453 0.9× 182 0.5× 177 0.9× 82 0.7× 199 2.3× 14 571
Elza Friedländer Hungary 7 370 0.7× 293 0.9× 223 1.2× 47 0.4× 32 0.4× 7 530
R. Borson United States 5 574 1.2× 425 1.3× 121 0.6× 97 0.8× 52 0.6× 7 682
Jennifer A. Lacap France 8 418 0.8× 149 0.4× 146 0.8× 227 1.8× 96 1.1× 12 558
Roberta Guzman United States 8 539 1.1× 289 0.9× 235 1.2× 107 0.9× 248 2.8× 11 684

Countries citing papers authored by Jeff Sperinde

Since Specialization
Citations

This map shows the geographic impact of Jeff Sperinde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Sperinde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Sperinde more than expected).

Fields of papers citing papers by Jeff Sperinde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Sperinde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Sperinde. The network helps show where Jeff Sperinde may publish in the future.

Co-authorship network of co-authors of Jeff Sperinde

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Sperinde. A scholar is included among the top collaborators of Jeff Sperinde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Sperinde. Jeff Sperinde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Razis, Evangelia, Georgia-Angeliki Koliou, Eleftheria Tsolaki, et al.. (2021). Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer. Anticancer Research. 41(4). 1793–1802. 6 indexed citations
2.
Chumsri, Saranya, Jeff Sperinde, Heshan Liu, et al.. (2018). High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clinical Cancer Research. 24(13). 3053–3058. 23 indexed citations
3.
Sperinde, Jeff, Weidong Huang, Aki Vehtari, et al.. (2018). p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. Clinical Cancer Research. 24(13). 3046–3052. 14 indexed citations
4.
5.
Growdon, Whitfield B., Jolijn W. Groeneweg, Darrell R. Borger, et al.. (2015). HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant. Gynecologic Oncology. 137(1). 160–166. 30 indexed citations
6.
Sperinde, Jeff, Weidong Huang, Aki Vehtari, et al.. (2015). Quantitative p95HER2 and HER2 correlations with outcome in the FinHer trial. Cancer Research. 75(9). 1 indexed citations
7.
Duchnowska, Renata, Jeff Sperinde, Ahmed Chenna, et al.. (2015). Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro-Oncology. 17(9). 1241–9. 24 indexed citations
8.
Sperinde, Jeff, Weidong Huang, Aki Vehtari, et al.. (2015). Abstract P3-06-03: Quantitative p95HER2 and HER2 correlations with outcome in the FinHer trial. Cancer Research. 75(9_Supplement). P3–6. 1 indexed citations
9.
Duchnowska, Renata, Jeff Sperinde, Ahmed Chenna, et al.. (2014). Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff. Clinical Cancer Research. 20(10). 2805–2813. 27 indexed citations
10.
Montemurro, Filippo, Aleix Prat, Valentina Rossi, et al.. (2013). Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer. Molecular Oncology. 8(1). 20–26. 35 indexed citations
11.
Tolaney, Sara M., Julie Najita, Jeff Sperinde, et al.. (2013). A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Annals of Oncology. 24(7). 1841–1847. 8 indexed citations
12.
Biernat, Wojciech, Renata Duchnowska, Tomasz Trojanowski, et al.. (2012). Quantitative HER2 levels and steroid receptor expression in primary breast cancers and in matched brain metastases.. Journal of Clinical Oncology. 30(15_suppl). 603–603. 1 indexed citations
13.
Duchnowska, Renata, Wojciech Biernat, Barbara Szostakiewicz, et al.. (2012). Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2+ Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy. The Oncologist. 17(1). 26–35. 27 indexed citations
14.
Ghosh, Ritwik, Archana Narasanna, Shizhen Emily Wang, et al.. (2011). Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers. Cancer Research. 71(5). 1871–1882. 171 indexed citations
15.
Joensuu, Heikki, Jeff Sperinde, M. Leinonen, et al.. (2011). Very high quantitative tumor HER2 content and outcome in early breast cancer. Annals of Oncology. 22(9). 2007–2013. 20 indexed citations
16.
Bates, Michael, Jeff Sperinde, Wolfgang J. Köstler, et al.. (2011). Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Annals of Oncology. 22(9). 2014–2020. 24 indexed citations
17.
Lipton, Allan, Wolfgang J. Köstler, Kim Leitzel, et al.. (2010). Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization‐positive patients with metastatic breast cancer treated with trastuzumab. Cancer. 116(22). 5168–5178. 38 indexed citations
18.
19.
Desmedt, Christine, Jeff Sperinde, Fanny Piette, et al.. (2009). Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH. Diagnostic Molecular Pathology. 18(1). 22–29. 31 indexed citations
20.
Sperinde, Jeff, Suhail M. Ali, Kim Leitzel, et al.. (2009). Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Journal of Clinical Oncology. 27(15_suppl). 1059–1059.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marcia R. Campbell Breakdown of academic impact, for papers by Xander Munroe Breakdown of academic impact, for papers by Josep Lluís Parra-Palau Breakdown of academic impact, for papers by Ioannis Roxanis Breakdown of academic impact, for papers by Yen-Chao Wang Breakdown of academic impact, for papers by M. Pegram Breakdown of academic impact, for papers by Elza Friedländer Breakdown of academic impact, for papers by R. Borson Breakdown of academic impact, for papers by Jennifer A. Lacap Breakdown of academic impact, for papers by Roberta Guzman
Rankless by CCL
2026